Compare Ascendis Pharma A/S (ASND) vs Sunrun Inc (RUN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Sunrun Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Sunrun Inc trades at $12.46 (market cap $2.97B). The key difference: Ascendis Pharma A/S is far larger — about 6× Sunrun Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| ASND | RUN | |
|---|---|---|
Market Cap | $17.74B | $2.97B |
Sector | Health | Technology |
52-Week High | $277.18 | $21.41 |
52-Week Low | $163.32 | $9.07 |
Enterprise Value | $18.11B | $17.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Sunrun (RUN) trades at $12.47, up 0.08% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong profitability with a net income margin of 17.88% and ROE of 19.06%, while launching a distributed AI data center pilot to leverage its home energy assets. Analyst consensus is bullish with a $17.45 price target, but cash flow from operations remains negative, highlighting financial strain.
The outlook for RUN is mixed: growth potential from virtual power plant initiatives and AI partnerships offers upside, but negative operating cash flow and high debt pose significant risks. Investors should weigh the attractive valuation multiples against operational sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
